Novostia
PrivateLast Round
VC Round
Sep 17, 2024
Total Funding Raised
$8.18M
Company Overview
Novostia SA is a medical device company developing an innovative artificial heart valve designed to not require lifelong anticoagulant medication.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials, Advanced Materials
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Novostia Comparables
Compare Novostia with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Foldax Inc. | 88% | |
| Xeltis | 80% | |
| Corcym | 76% | |
Novostia Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Sep 17, 2024 | ||||
| Series A | May 2, 2023 | ||||
| Series A | May 1, 2023 | ||||
| Grant | Jan 14, 2020 | ||||
| VC Round | Feb 22, 2019 |
Novostia Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 25, 2026
Web traffic grew 115% MoM (from 313 to 673 monthly visitors)
- May 1, 2023
$2.7M round raised
Novostia Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Novostia's valuation, stock price, and market status.